Compare Biogen Inc (BIIB) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Unity Software Inc — how do they compare? Biogen Inc trades at $191.9 (market cap $30.86B), while Unity Software Inc trades at $31.79 (market cap $13.39B). The key difference: Biogen Inc is far larger — about 2.3× Unity Software Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | U | |
|---|---|---|
Market Cap | $30.86B | $13.39B |
Sector | Health | Technology |
52-Week High | $216.63 | $49.47 |
52-Week Low | $122.68 | $17.13 |
Enterprise Value | $33.14B | $13.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Unity Software (U) trades at $30.68, down 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $36.50. Recent earnings show mixed results, with Q3 2025 beating expectations but subsequent quarters missing, while revenue remains stable around $1.8 billion. The company maintains strong gross margins of 62.79% but reports negative net income margins, reflecting ongoing profitability challenges amid strategic shifts toward AI and advertising.
The outlook for Unity hinges on its AI integration and cost management, offering upside if execution improves, but risks include persistent losses, high debt, and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
